Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SK-1405
- Development stage
- Phase 2
- Lead developer
- Sanwa Kagaku Kenkyusho
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
SK-1405 is an oral small molecule drug developed for the treatment of pruritus, particularly uremic pruritus in patients with renal failure. The drug has been under clinical development in Japan, with Sanwa Kagaku Kenkyusho and UBE Corp. involved as developers. Its primary indication is for skin and musculoskeletal diseases related to pruritus, especially in hemodialysis patients[1][2][3][7]. The precise mechanism of action has not been explicitly stated in public sources; however, clinical trials have focused on receptor occupancy studies and efficacy for uremic pruritus[4][5].
02
Targets
MOR (Mu opioid receptor)
Beyond the preview
Go deeper on SK-1405.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SK-1405.